cmcmaster/rheumatology-biologics-dataset · Datasets at Hugging Face

pbs_code stringlengths 5 6	drug stringclasses 17 values	brand stringclasses 30 values	formulation stringclasses 37 values	indication stringclasses 8 values	treatment_phase stringclasses 57 values	streamlined_code stringclasses 33 values	online_application bool 2 classes	authority_method stringclasses 2 values	hospital_type stringclasses 3 values	schedule_code int64 3.47k 3.47k	schedule_year int64 2.02k 2.02k	schedule_month stringclasses 1 value
11488P	infliximab	Inflectra	Powder for I.V. infusion 100 mg	ankylosing spondylitis	First continuing treatment	14689	true	STREAMLINED	Private	3,471	2,024	NOVEMBER
11488P	infliximab	Renflexis	Powder for I.V. infusion 100 mg	ankylosing spondylitis	First continuing treatment	14689	true	STREAMLINED	Private	3,471	2,024	NOVEMBER
11488P	infliximab	Inflectra	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Subsequent continuing treatment	14723	true	STREAMLINED	Private	3,471	2,024	NOVEMBER
11488P	infliximab	Renflexis	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Subsequent continuing treatment	14723	true	STREAMLINED	Private	3,471	2,024	NOVEMBER
13054C	infliximab	Remsima SC	Solution for injection 120 mg in 1 mL pre-filled pen	psoriatic arthritis	Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11743C	tocilizumab	Actemra Subcutaneous Injection	Injection 162 mg in 0.9 mL single use pre-filled syringe	giant cell arteritis	Initial treatment	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12566J	infliximab	Remsima SC	Solution for injection 120 mg in 1 mL pre-filled pen	rheumatoid arthritis	Balance of supply for Initial treatment, Continuing treatment - subcutaneous form	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9085E	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9085E	etanercept	Brenzys	Injections 50 mg in 1 mL single use pre-filled syringes, 4	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9085E	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9085E	etanercept	Brenzys	Injections 50 mg in 1 mL single use pre-filled syringes, 4	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9085E	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9085E	etanercept	Brenzys	Injections 50 mg in 1 mL single use pre-filled syringes, 4	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9085E	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9085E	etanercept	Brenzys	Injections 50 mg in 1 mL single use pre-filled syringes, 4	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13222X	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13222X	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13222X	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13222X	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12621G	upadacitinib	Rinvoq	Tablet 15 mg	ankylosing spondylitis	Continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12621G	upadacitinib	Rinvoq	Tablet 15 mg	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13227E	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled pen	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13227E	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled pen	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13227E	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled pen	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13227E	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled pen	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
11721X	tocilizumab	Actemra Subcutaneous Injection	Injection 162 mg in 0.9 mL single use pre-filled syringe	giant cell arteritis	Continuing treatment	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13069W	infliximab	Remsima SC	Solution for injection 120 mg in 1 mL pre-filled syringe	ankylosing spondylitis	Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11490R	infliximab	Renflexis	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Subsequent continuing treatment	14504	true	STREAMLINED	Public	3,471	2,024	NOVEMBER
11490R	infliximab	Remicade	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Subsequent continuing treatment	14504	true	STREAMLINED	Public	3,471	2,024	NOVEMBER
11490R	infliximab	Inflectra	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Subsequent continuing treatment	14504	true	STREAMLINED	Public	3,471	2,024	NOVEMBER
13078H	infliximab	Remsima SC	Solution for injection 120 mg in 1 mL pre-filled syringe	psoriatic arthritis	Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13049T	infliximab	Remsima SC	Solution for injection 120 mg in 1 mL pre-filled pen	ankylosing spondylitis	Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13722F	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13299Y	tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	juvenile idiopathic arthritis	Continuing treatment	14093	true	STREAMLINED	Public	3,471	2,024	NOVEMBER
13293P	adalimumab	Humira	Injection 20 mg in 0.2 mL pre-filled syringe	juvenile idiopathic arthritis	Continuing treatment	14136	true	STREAMLINED	Public	3,471	2,024	NOVEMBER
11198J	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11198J	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11198J	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	psoriatic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11198J	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	psoriatic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12363Q	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12028C	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	non-radiographic axial spondyloarthritis	Continuing treatment	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5605B	abatacept	Orencia	Powder for I.V. infusion 250 mg	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5605B	abatacept	Orencia	Powder for I.V. infusion 250 mg	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5605B	abatacept	Orencia	Powder for I.V. infusion 250 mg	rheumatoid arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5605B	abatacept	Orencia	Powder for I.V. infusion 250 mg	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5605B	abatacept	Orencia	Powder for I.V. infusion 250 mg	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5605B	abatacept	Orencia	Powder for I.V. infusion 250 mg	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
12439Q	adalimumab	Amgevita	Injection 20 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
12439Q	adalimumab	Amgevita	Injection 20 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
12439Q	adalimumab	Amgevita	Injection 20 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
12439Q	adalimumab	Amgevita	Injection 20 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
9455P	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9455P	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9455P	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9455P	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9455P	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9455P	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9455P	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9455P	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10909E	certolizumab pegol	Cimzia	Injection 200 mg in 1 mL single use pre-filled syringe	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10909E	certolizumab pegol	Cimzia	Injection 200 mg in 1 mL single use pre-filled syringe	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10909E	certolizumab pegol	Cimzia	Injection 200 mg in 1 mL single use pre-filled syringe	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10073E	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	juvenile idiopathic arthritis	Continuing Treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
10073E	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
10073E	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
10073E	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
10073E	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	juvenile idiopathic arthritis	Continuing treatment	null	false	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
10073E	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
5733R	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5733R	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5733R	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5733R	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
12796L	tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	juvenile idiopathic arthritis	Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
12796L	tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	juvenile idiopathic arthritis	Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
12624K	upadacitinib	Rinvoq	Tablet 15 mg	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12624K	upadacitinib	Rinvoq	Tablet 15 mg	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12624K	upadacitinib	Rinvoq	Tablet 15 mg	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12624K	upadacitinib	Rinvoq	Tablet 15 mg	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER

11488P

infliximab

Inflectra

Powder for I.V. infusion 100 mg

ankylosing spondylitis

First continuing treatment

14689

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

11488P

infliximab

Renflexis

Powder for I.V. infusion 100 mg

ankylosing spondylitis

First continuing treatment

14689

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

11488P

infliximab

Inflectra

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Subsequent continuing treatment

14723

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

11488P

infliximab

Renflexis

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Subsequent continuing treatment

14723

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

13054C

infliximab

Remsima SC

Solution for injection 120 mg in 1 mL pre-filled pen

psoriatic arthritis

Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11743C

tocilizumab

Actemra Subcutaneous Injection

Injection 162 mg in 0.9 mL single use pre-filled syringe

giant cell arteritis

Initial treatment

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12566J

infliximab

Remsima SC

Solution for injection 120 mg in 1 mL pre-filled pen

rheumatoid arthritis

Balance of supply for Initial treatment, Continuing treatment - subcutaneous form

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9085E

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9085E

etanercept

Brenzys

Injections 50 mg in 1 mL single use pre-filled syringes, 4

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9085E

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9085E

etanercept

Brenzys

Injections 50 mg in 1 mL single use pre-filled syringes, 4

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9085E

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

ankylosing spondylitis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9085E

etanercept

Brenzys

Injections 50 mg in 1 mL single use pre-filled syringes, 4

ankylosing spondylitis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9085E

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9085E

etanercept

Brenzys

Injections 50 mg in 1 mL single use pre-filled syringes, 4

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13222X

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13222X

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13222X

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13222X

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12621G

upadacitinib

Rinvoq

Tablet 15 mg

ankylosing spondylitis

Continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12621G

upadacitinib

Rinvoq

Tablet 15 mg

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13227E

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled pen

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13227E

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled pen

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13227E

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled pen

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13227E

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled pen

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

11721X

tocilizumab

Actemra Subcutaneous Injection

Injection 162 mg in 0.9 mL single use pre-filled syringe

giant cell arteritis

Continuing treatment

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13069W

infliximab

Remsima SC

Solution for injection 120 mg in 1 mL pre-filled syringe

ankylosing spondylitis

Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11490R

infliximab

Renflexis

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Subsequent continuing treatment

14504

true

STREAMLINED

Public

3,471

2,024

NOVEMBER

11490R

infliximab

Remicade

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Subsequent continuing treatment

14504

true

STREAMLINED

Public

3,471

2,024

NOVEMBER

11490R

infliximab

Inflectra

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Subsequent continuing treatment

14504

true

STREAMLINED

Public

3,471

2,024

NOVEMBER

13078H

infliximab

Remsima SC

Solution for injection 120 mg in 1 mL pre-filled syringe

psoriatic arthritis

Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13049T

infliximab

Remsima SC

Solution for injection 120 mg in 1 mL pre-filled pen

ankylosing spondylitis

Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13722F

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13299Y

tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

juvenile idiopathic arthritis

Continuing treatment

14093

true

STREAMLINED

Public

3,471

2,024

NOVEMBER

13293P

adalimumab

Humira

Injection 20 mg in 0.2 mL pre-filled syringe

juvenile idiopathic arthritis

Continuing treatment

14136

true

STREAMLINED

Public

3,471

2,024

NOVEMBER

11198J

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

psoriatic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11198J

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

psoriatic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11198J

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

psoriatic arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11198J

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

psoriatic arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12363Q

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12028C

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

non-radiographic axial spondyloarthritis

Continuing treatment

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5605B

abatacept

Orencia

Powder for I.V. infusion 250 mg

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5605B

abatacept

Orencia

Powder for I.V. infusion 250 mg

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5605B

abatacept

Orencia

Powder for I.V. infusion 250 mg

rheumatoid arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5605B

abatacept

Orencia

Powder for I.V. infusion 250 mg

rheumatoid arthritis

First continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5605B

abatacept

Orencia

Powder for I.V. infusion 250 mg

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5605B

abatacept

Orencia

Powder for I.V. infusion 250 mg

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

12439Q

adalimumab

Amgevita

Injection 20 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

12439Q

adalimumab

Amgevita

Injection 20 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

12439Q

adalimumab

Amgevita

Injection 20 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

12439Q

adalimumab

Amgevita

Injection 20 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

9455P

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9455P

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9455P

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9455P

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9455P

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

ankylosing spondylitis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9455P

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

ankylosing spondylitis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9455P

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9455P

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10909E

certolizumab pegol

Cimzia

Injection 200 mg in 1 mL single use pre-filled syringe

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10909E

certolizumab pegol

Cimzia

Injection 200 mg in 1 mL single use pre-filled syringe

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10909E

certolizumab pegol

Cimzia

Injection 200 mg in 1 mL single use pre-filled syringe

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10073E

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

juvenile idiopathic arthritis

Continuing Treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

10073E

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

10073E

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

10073E

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

10073E

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

juvenile idiopathic arthritis

Continuing treatment

null

false

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

10073E

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

5733R

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5733R

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5733R

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5733R

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

12796L

tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

juvenile idiopathic arthritis

Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

12796L

tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

juvenile idiopathic arthritis

Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

12624K

upadacitinib

Rinvoq

Tablet 15 mg

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12624K

upadacitinib

Rinvoq

Tablet 15 mg

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12624K

upadacitinib

Rinvoq

Tablet 15 mg

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12624K

upadacitinib

Rinvoq

Tablet 15 mg

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER